• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    U

    UCB (company)

    企业
    3,085论文总数
    9.2万引用总数

    UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology. Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee.

    论文量&引用量时间轴

    机构学者

    论文(3085)

    年份
    起
    –
    止
    排序
    1Above-Filter Digestion Proteomics Reveals Drug Targets and Localizes Ligand Binding Site
    Bohdana Sokolova,Hassan Gharibi, Maryam Jafari, Hezheng Lyu,Silvia Lovera,Massimiliano Gaetani,Amir Ata Saei,Roman A Zubarev

    Identifying how drugs interact with proteins is fundamental to understanding their therapeutic effects and side effects. While numerous chemical proteomics methods exist for determining protein targets of drugs, each exhibits “blind spots,” necessitating complementary approaches. We introduce Above-Filter Digestion Proteomics (AFDIP), which monitors trypsin digestion rates that decrease at ligand-binding sites, while potentially increasing elsewhere. Molecular dynamics simulations showed that these changes relate to backbone flexibility. Using AFDIP, we identified targets of various drugs and metabolites, allowing two-dimensional analysis with the drug concentration as the second dimension. The method identifies binding sites within ≤10 Å of crystallography-determined locations with improved resolution (≤5 Å) for larger proteins. Compared with existing proteolysis approaches, AFDIP offers simpler sample preparation, deeper proteome analysis, and broader sequence coverage. AFDIP addresses the blind spots of current techniques and provides structural insights, enhancing the chemical proteomics toolkit.

    2026Journal of proteome research(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
    Philip J. Mease,Richard B. Warren,Peter Nash,Jean-Marie Grouin,Nikos Lyris,Damon Willems,Vanessa Taieb,Jason Eells,Iain B. McInnes

    The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR) was assessed at 52 weeks (Wk52) using matching-adjusted indirect comparisons (MAIC). Relevant trials were systematically identified. For patients who were bDMARD naïve, individual patient data (IPD) from BE OPTIMAL (NCT03895203; N = 431) were matched with summary data from KEEPsAKE-1 (NCT03675308; N = 483). For patients who were TNFi-IR, IPD from BE COMPLETE (NCT03896581; N = 267) were matched with summary data from the TNFi-IR patient subgroup in KEEPsAKE-2 (NCT03671148; N = 106). To adjust for cross-trial differences, patients from the bimekizumab trials were re-weighted to match the baseline characteristics of patients in the risankizumab trials. Adjustment variables were selected based on expert consensus (n = 5) and adherence to established MAIC guidelines. Recalculated bimekizumab Wk52 outcomes for American College of Rheumatology (ACR) 20/50/70 response criteria and minimal disease activity (MDA) index (non-responder imputation) were compared with risankizumab outcomes via non-placebo-adjusted comparisons. In patients who were bDMARD naïve, bimekizumab had a significantly greater likelihood of response than risankizumab at Wk52 for ACR50 (odds ratio [95

    2026Rheumatology and Therapy(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3A Robust Meta-Analytic Approach for Evaluating Regional Treatment Effect in a Multi-Regional Clinical Trial
    Naoki Isogawa,Satrajit Roychoudhury, Marc Vandemeulebroecke, Foteini Strimenopoulou,Wenjin Wang

    A multi-regional clinical trial under one protocol is the gold standard in global drug development. In addition to the positive benefit-risk ratio in the overall population, evaluating local treatment effects and assessing regional consistency are significant components of labeling discussions with the local health authorities. However, relatively small sample sizes in some regions lead to lower precision in the local treatment effect estimates. Such hurdles can be overcome by using results from other regions while estimating the region-specific treatment effect. Commonly used methods are complete pooling of data from specific regions assuming constant effect, and a Bayesian hierarchical model assuming exchangeability or similarity. Pooling patient data from multiple regions increases the precision of the treatment effect estimated in one region provided the medical practice is similar across regions. However, such an approach ignores heterogeneity between different regions and can cause an unrealistic estimate. On the other hand, the Bayesian hierarchical model considers the between-region heterogeneity and provides shrinkage estimates for region-specific treatment effects. However, shrinkage estimators are often criticized for providing too optimistic information borrowing in the presence of outliers. This article presents a robust meta-analytic approach for estimating region-specific treatment effects. While improving the precision, the proposed assessment is less influenced by other regions and provides a more robust estimation of the treatment effect. Simulation studies and a real-life example illustrate the proposed methodology.

    2026JOURNAL OF BIOPHARMACEUTICAL STATISTICS(2026)
    引用
    AI阅读
    加入学术空间
    4Short-term Outcomes, Longer-Term Disability and Relapse Risk in LGI1-antibody Encephalitis
    Sudarshini Ramanathan,John Soltys,Sophia Michael, Samuel V Mackrill,Jonathan Cleaver,Robyn Williams,Mateusz Makuch,Patrick Waters, Yaacov Ansizka,Alessandro Dinoto, Mohsen Farazdaghi,Benjamin Trewin,

    Abstract Leucine-rich glioma-inactivated-1 antibody encephalitis (LGI1-Ab-E) is a common and immunotherapy-responsive form of encephalitis. However, it is not known which immunotherapy regimens improve short-term outcomes, longer-term disability and relapse risk. Further, it is not known if the widely-utilised modified Rankin Scale (mRS) accurately captures quality of life (QoL) in LGI1-Ab-E, complicating disability measurements and interpretation of immunotherapy responses. A multicentre, international, real-world comparative analysis of patients with LGI1-Ab-E. Retrospective data from patient records evaluated short-term seizure and cognitive outcomes, 1-6 year disability, and future relapse risk associations, by integrating demographics, clinical features investigations and exposures to immunotherapies and antiseizure medications (ASMs). Patient- and neurologist-rated QoL assessments were used to establish an evidence-based mRS threshold for defining clinically significant disability. Cox proportional hazard models, Anderson-Gill, and generalised linear mixed-effects models were employed. 181 patients were included, with median age at onset 63 years (range 23 - 92); 122/181 (67%) were male. Short-term outcomes, evaluated at both five and ten weeks post-treatment initiation, identified exposure to immunotherapies associated with seizure resolution (OR = 13.97, 95%CI = 6.10-32.01; p < 0.0001 and OR = 8.53, 95%CI = 4.14-17.55; p < 0.0001, respectively), notably with corticosteroids, plasma exchange and rituximab, but not ASMs, intravenous immunoglobulins or steroid sparing agents. Conversely, seizure recurrence was observed after discontinuation of oral prednisolone, but not other immunotherapies or ASMs (OR = 39.53, 95%CI = 12.70-122.20, p < 0.0001). To evaluate longer-term disability, first, mRS scores were calibrated using QoL assessments: this identified a significant increase in patient-rated disability at mRS score of 2. Hence, using mRS 0-1 as a favourable outcome, we identified worse mRS at nadir associated with greater one-year disability (OR = 2.56, 95%CI = 1.56–4.20, p = 0.0003), and each month of delayed immunotherapy associated with a 16% increased risk of disability (HR = 1.16, 95%CI = 1.06-1.35, p = 0.004). Additionally, absence of immunotherapy associated both with greater one-year disability (OR = 5.67; 95% CI 1.19-26.54, p = 0.03) and a relapsing course (OR = 7.64, 95%CI = 2.51-21.77, p = 0.0002). Both a relapsing course, observed in 38% of patients, and the number of relapses associated with step-wise worsening of disability and QoL-outcomes. Rituximab exposure was the only identified clinical factor associated with reduced future relapse risk, by 93% (HR = 0.07, 95%CI = 0.01-0.48, p = 0.002). Persistent serum LGI1-IgMs, but not LGI1-IgGs, at one-year, associated with future relapses (HR = 11.69, 95%CI = 1.58-145.80, p = 0.02). Distinctive clinical factors and select immunotherapies, particularly intravenous methylprednisolone and plasma exchange, but not ASMs, associated with favourable short-term outcomes, patient-centric longer-term disability and relapses in LGI1-Ab-E. Our findings provide evidence-based disability thresholds, highlight novel prognostic biomarkers, and pragmatically guide LGI1-Ab-E care, pending randomized clinical trials.

    2026Brain(2026)
    引用
    AI阅读
    加入学术空间
    5Pulmonary Safety of Staccato Alprazolam in Healthy Participants and Participants with Mild Asthma: Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial.
    S David Miller, Craig F LaForce, Laura Barlow, Shikiko Watanabe,Aliceson King, Maria Burian,Hugues Chanteux

    Staccato alprazolam (STAP) is a hand-held device that can provide rapid systemic delivery of alprazolam via pulmonary inhalation. UP0099/NCT04802746, a phase 1, randomized, double-blind, placebo-controlled trial, evaluated pulmonary safety of two consecutive doses of STAP administered 72 h apart (days 1, 4). Part A evaluated STAP 1 mg and 2 mg vs. placebo in a three-way crossover design in healthy adults. Part B evaluated STAP 2 mg vs. placebo in a two-arm parallel-group design in adults with mild asthma. In Part A (n = 30 randomized) on day 1, mean change from baseline in forced expiratory volume in 1 s (FEV1) showed a statistically significant decrease vs. placebo at 5 min postdose for STAP 1 mg and 5/20 min for STAP 2 mg. On day 4, there were no statistically significant negative changes from baseline in FEV1. Respiratory treatment-emergent adverse events (TEAEs) were reported by 8/29 and 12/29 participants on STAP 1 mg/2 mg, respectively (day 1), and 8/29 and 9/28 (day 4) (placebo: 0). In Part B (n = 25 placebo, n = 23 STAP) on days 1 and 4, mean change from baseline in FEV1 showed a statistically significant decrease for STAP 2 mg vs. placebo at 5/20 min and 6 h postdose. Respiratory TEAEs were reported by 16/23 participants on STAP 2 mg on day 1, 15/22 on day 4 (placebo: 0). Most respiratory TEAEs were mild in intensity. No evidence of clinically relevant airway obstruction or respiratory TEAEs indicative of bronchospasm with STAP were observed. Two doses of STAP (1 mg/2 mg) administered 72 h apart were well tolerated in healthy participants and those with mild asthma.

    2026Pulmonary pharmacology & therapeutics(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 3085 篇论文

    合作机构(100)

    牛津大学合作论文 163
    莱顿大学合作论文 119
    俄勒冈健康与科学大学合作论文 107
    安进合作论文 98
    华盛顿大学合作论文 55
    曼彻斯特大学合作论文 54
    鲁尔波鸿大学合作论文 54
    加州大学旧金山分校合作论文 53
    加利福尼亚大学圣地亚哥分校合作论文 51
    卡罗琳斯卡医学院合作论文 50

    机构统计